Skip to main navigation

Media
Investors
Contact Us

Medicines
Careers

Our Science

Pipeline Explore our pipeline of investigational RAS(ON) inhibitors.
Tri-Complex Platform and RAS(ON) Biology Explore RAS(ON) biology and the platform driving targeted therapy discovery and development.
Research, Grants & Support Learn about funding, research collaboration, and community support at RevMed.
Publications Access scientific publications, congress presentations, and RAS(ON) research.

Our Stories

Revolution RAS Enter Revolution RAS, where the mindset behind Revolution Medicines comes to life. See what drives us, how we challenge convention, and why we are taking on RAS-addicted cancers.
Stories Perspectives about our science, our people, RAS-addicted cancers, and life at Revolution Medicines.

Our Company

About RevMed Learn about our mission, values, and the team advancing therapies for RAS-addicted cancers.
Responsibility Learn about our approach to pricing and patient access, and corporate responsibility.

Medicines
- Revolution RAS Enter Revolution RAS, where the mindset behind Revolution Medicines comes to life. See what drives us, how we challenge convention, and why we are taking on RAS-addicted cancers.
- Stories Perspectives about our science, our people, RAS-addicted cancers, and life at Revolution Medicines.
- About RevMed Learn about our mission, values, and the team advancing therapies for RAS-addicted cancers.
- Responsibility Learn about our approach to pricing and patient access, and corporate responsibility.
Careers
Media
Investors
Contact Us

Events & Presentations

Investor Relations

Events & Presentations

Governance

Governance Overview Board of Directors Management

Stock Information

Stock Quote & Chart Analyst Coverage

EQRx Acquisition Information

IRS Form 8937 for EQRx Shareholders

Resources

Investor FAQs Email Alerts Contact IR

Presentations

RASONQUE Approval Investor Presentation

August 26, 2026

Revolution Medicines Corporate Presentation

August 5, 2026

Upcoming Events

November 4, 2026 4:30 PM EST

Revolution Medicines Q3 2026 Earnings Conference Call

Past Events

August 26, 2026 1:30 PM EDT

RASONQUE FDA Approval Investor Update

August 5, 2026 4:30 PM EDT

Revolution Medicines Q2 2026 Earnings Conference Call

On Target
to Outsmart Cancer

Our Science

Pipeline
Tri-Complex Platform and RAS(ON) Biology
Research, Grants & Support
Publications

Our Medicines

Medicines

Our Stories

Revolution RAS
Stories

Our Company

About Us
Responsibility
Pre-Approval Access
Careers
Contact Us

© 2026 Revolution Medicines, Inc.

Consumer Health Data Privacy Notice
Global Privacy Notice